🇺🇸 FDA
Patent

US 11045558

RPGR gene therapy for retinitis pigmentosa

granted A61KA61K48/005A61K9/0048

Quick answer

US patent 11045558 (RPGR gene therapy for retinitis pigmentosa) held by The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K48/005, A61K9/0048, A61P, A61P27/02